Long Term Bio
Long only, biotech, healthcare, short only

Rexahn: A Turn Around Story For 2014

Rexahn has established a huge pipeline of oncology drugs that may change the way cancers are treated in the future. There is a variety of compounds to limit the risk profile of the company, and allow investors to establish some type of speculative position. We see potential upside of at least 300% rise in share price in the coming year.

There are many biotechs out there that attempt to create new molecules for the treatment of today's deadliest forms of cancer. With the speculative nature of these oncology biotechs brings some massive speculation with overblown share prices. Despite this there is one company that has been undervalued in the oncology space for the longest time trading currently at $0.43 per...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details